Genetic Technologies trades as part of the medical diagnostics and research industry and trades as part of the healthcare sector. The company CEO is Paul A. Kasian. Genetic Technologies is a molecular diagnostics company which offers predictive testing and assessment tools to help physicians manage women’s health. It has developed BREVAGenplus, which is a is a clinically validated risk assessment test.
Previous Intraday Performance:
The GENE shares had a previous change of -3.51% which opened at 0.81 and closed at 0.81. It moved to an intraday high of 0.84 and a low of 0.80.
Over the last five trading days, GENE shares returned -11.82% and in the past 30 trading days it returned -2.56%. Over three months, it changed 35.04%. In one year it has changed -34.65% and within that year its 52-week high was 2.04 and its 52-week low was 0.51. GENE stock is 58.28% above its 52 Week Low.
Our calculations result in a 200 day moving average of 1.01 and a 50 day moving average of 0.84. Right now, GENE stock is trading -20.04% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $14.3m with 17.6m shares outstanding and a float of 17.6m shares. Trading volume was 33,188 shares and has experienced an average volume of 49,396 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Genetic Technologies was 0 which ended on 30th of June 2018.
Below was the last reported quarterly earnings per share:
06-30-2018: 0.00 (estimated)
The next earnings report will be: 03-27-2019
The long-term trend of the EPS is a vital number as it helps understand the future potential of Genetic Technologies.
Indicators Also to Watch:
Based on the latest filings, there is 4.30% of institutional ownership.
I calculated the beta to be 3.99
Based on last reported financials, the company’s return on equity is -69.60%, return on assets is -58.31%, price-to-sales is 232.21 and price-to-book is 4.76.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result